Article
Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2016
Kumpiro Siriluk, Sriuranpong Virote, Areepium Nutthada
Abstract excerpt
BACKGROUND: Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less than 20%. One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm. PURPOSE: To establish both prevalence of CTR1 polymorphism and its impact on treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.